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Purpose: To evaluate conjunctival hyperemia associated with bimatoprost 0.01% treatment 
in patients who replace latanoprost 0.005% with bimatoprost 0.01%.
Methods: Randomized, double-masked, vehicle-controlled, multicenter study of patients with 
ocular hypertension or glaucoma whose intraocular pressure (IOP) was adequately controlled on 
latanoprost monotherapy. At baseline, patients discontinued latanoprost and were   randomized 
to treatment with once-daily bimatoprost 0.01% (n = 151) or vehicle (n = 71). The primary 
endpoint was the peak change in macroscopic hyperemia (conjunctival hyperemia evaluated 
by gross visual inspection) from baseline to month 1.
Results: Bimatoprost 0.01% was noninferior to vehicle in the mean [standard deviation] 
peak change from baseline macroscopic hyperemia at month 1 (0.18 [0.46] in the bimatoprost 
0.01% group vs 0.02 [0.32] in the vehicle group, P = 0.009). The between-group difference was 
0.15 (95% confidence interval [CI]: 0.04, 0.26), which was within the predefined margin for 
  noninferiority of 0.5 on a hyperemia grading scale of 0 to +3. There were no   statistically signifi-
cant between-group differences in the percentage of patients with a $1-grade increase in macro-
scopic hyperemia from baseline. Mean IOP was decreased from baseline (-0.7 to -1.3 mm Hg) in 
the bimatoprost 0.01% group (P # 0.002) and was increased from baseline (+3.3 to +3.6 mm Hg) 
in the vehicle group (P , 0.001) at month 1. There were no statistically   significant between-
group differences in adverse events.
Conclusions: Bimatoprost 0.01% was noninferior to vehicle with respect to conjunctival 
hyperemia in this study population. Replacement of latanoprost with bimatoprost 0.01% in 
patients with ocular hypertension or glaucoma can result in additional IOP reduction without 
clinically important hyperemia.
Keywords: conjunctiva, glaucoma, hyperemia, intraocular pressure, prostaglandin analogs, 
topical drug administration
Introduction
Glaucoma is an optic neuropathy that is treated by lowering intraocular pressure (IOP). 
Prostaglandin analogs including latanoprost, bimatoprost, and travoprost are currently 
the most effective topical medications available for reducing IOP.1 These medications, 
which are well-tolerated, systemically safe, and conveniently dosed once-daily, have 
become common first-line treatments for glaucoma.2
Patient adherence and persistence with medications is frequently an issue in diseases 
such as glaucoma that are chronic and generally asymptomatic. Factors potentially 
  affecting adherence and persistence with treatment include patient understanding of the Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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need for treatment and the convenience, cost, and side effects of 
treatment.3,4 The most common side effect of the prostaglandin 
analogs is conjunctival hyperemia,5 which is believed to result 
from nitric–oxide–mediated vasodilatation in the conjunctiva.6,7 
Although the redness is reversible and not associated with 
inflammation,7–9 conjunctival hyperemia led to the discon-
tinuation of 1.3% to 3.4% of patients treated with bimatoprost 
0.03%, latanoprost 0.005%, and travoprost 0.004% in their 
respective 6-month pivotal trials.10–12 Moreover, patients may 
be more likely to discontinue treatment due to side effects in 
clinical practice than in controlled clinical trials.13
Meta-analyses of randomized, controlled clinical trials 
have indicated that bimatoprost 0.03% reduces IOP more 
effectively than latanoprost 0.005%, but is associated with a 
higher incidence of conjunctival hyperemia.14,15 Conjunctival 
hyperemia associated with bimatoprost 0.03% treatment 
is typically mild and usually decreases over time during 
treatment.5,10,16 The occurrence of conjunctival hyperemia 
with bimatoprost has been shown to be related to the dose17 
and the frequency of dosing.8
A new formulation of bimatoprost has been developed to 
maintain the efficacy and improve the tolerability of bimato-
prost treatment. In the reformulation, the concentration of 
bimatoprost was reduced from 0.03% to 0.01%. A 1-year, 
parallel-group clinical study comparing the new bimatoprost 
0.01% formulation with the original bimatoprost 0.03% 
  formulation reported equivalent efficacy and improved safety 
with the new formulation.18 Bimatoprost 0.01% was better-
tolerated and associated with less conjunctival hyperemia 
compared with bimatoprost 0.03%.
The purpose of this masked, controlled study was to 
further evaluate bimatoprost 0.01% and the conjunctival 
hyperemia associated with bimatoprost 0.01% treatment in 
patients who replace latanoprost with bimatoprost with no 
washout between treatments. This strategy of replacement 
of latanoprost with bimatoprost may be done in practice to 
achieve better IOP control in selected patients.19 Our primary 
hypothesis was that in patients controlled on latanoprost 
therapy who replace latanoprost with bimatoprost 0.01%, 
the change in conjunctival hyperemia is no worse than that 
seen in patients who replace latanoprost with a vehicle. 
A secondary hypothesis was that bimatoprost 0.01% would 
provide a statistically significant reduction in IOP from the 
latanoprost-treated baseline despite the reduced   concentration 
of bimatoprost.
Material and methods
This was a randomized, double-masked, vehicle-  controlled, 
multicenter (15 sites), parallel-group comparison study 
  evaluating conjunctival hyperemia associated with   bimatoprost 
0.01% treatment. The study was approved by the institutional 
review board at each site and all patients provided written 
informed consent.
Patient eligibility was evaluated at a screening visit and 
confirmed at a baseline visit two days to three weeks later. 
Patients at least 18 years old, with a diagnosis of ocular 
hypertension or glaucoma associated with elevated IOP 
in each eye who, in the opinion of the investigator, were 
adequately controlled on latanoprost monotherapy and were 
able to go without IOP-lowering therapy for one month with-
out significant risk, were potentially eligible for the study. 
Patients were required to have been treated with latanoprost 
0.005% monotherapy in each eye for at least six weeks prior 
to the baseline visit. Patients were also required to have no 
more than 5 mm Hg of asymmetry of IOP between eyes at 
baseline and best-corrected visual acuity equivalent to a 
Snellen acuity of 20/100 or better in each eye. The primary 
exclusion criteria included: a score of 1 (mild) or greater for 
any ocular surface finding (including hyperemia) in either 
eye on macroscopic or on slit-lamp examination at baseline 
on latanoprost;   central corneal thickness ,500 microns 
or .600 microns in either eye at screening; uncontrolled 
  systemic disease; active ophthalmic disease other than glau-
coma that could interfere with the interpretation of the study 
data; known allergy or sensitivity to the study medication 
or its components; history of recurrent seasonal allergies 
within the past two years;   history of severe ocular trauma or 
refractive surgery at any time or laser, intraocular, or filtering 
surgery within three months prior to baseline; anticipated 
use of   topical   ophthalmic medication other than the study 
  medication   during the study; and anticipated change in 
preexisting therapy for systemic disease (eg, systemic beta-
blocker) that could affect IOP. Female patients who were 
pregnant, nursing, or of childbearing potential and not using 
reliable contraception were excluded from the study.
At the baseline study visit, patients discontinued latano-
prost therapy and were randomized in a 2:1 ratio to treatment 
with bimatoprost 0.01% or its vehicle administered in each 
eye, once-daily, in the evening for one month. The randomiza-
tion sequence was computer-generated and the randomization 
code was retained by the study sponsor and made available 
to the investigators only after the study had ended. The study 
medications were provided in identically masked bottles and 
the first dose was administered in the evening of the day of 
the baseline study visit.
Macroscopic hyperemia, defined as bulbar conjunctival 
hyperemia apparent on visual inspection, was evaluated by 
the investigator. A standard 5-point scoring system, based Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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on photographic standards for comparison, was used with 
the following descriptors: 0 (none) = normal, bulbar con-
junctival vessels easily observed; +0.5 (trace) = trace flush, 
reddish-pink color; +1 (mild) = mild flush, reddish color; 
+2 (moderate) = bright red color; and +3 (severe) = deep, 
bright, diffuse redness. Macroscopic hyperemia data were 
collected at 8 am, 12 pm, and 4 pm at the baseline visit and 
at a follow-up visit at month 1. The primary study endpoint 
was the peak change in macroscopic hyperemia from baseline 
to month 1, calculated for each eye by subtracting the largest 
score across the hourly measurements at baseline (the peak 
severity score at baseline) from the largest score across the 
hourly measurements at month 1 (the peak severity score 
at month 1). For each patient, the eye with the larger peak 
change in macroscopic hyperemia was used for analysis.
Secondary endpoints included the percentage of patients 
with a $1-unit increase in macroscopic hyperemia in either 
eye at each time point at month 1, the mean change from 
baseline IOP, safety measures, and health outcomes. IOP 
was measured with a Goldmann applanation tonometer 
using a 2-person reading method at 8 am, 12 pm, and 4 pm 
at the baseline and month 1 study visits. Two measurements 
were taken for each eye and a third measurement was taken 
if the difference between the first two measurements was 
greater than 2 mm Hg. The mean (of two measurements) or 
the median (of three measurements) was computed for each 
eye and the average of both eyes was used for each patient 
in the analyses.
Safety measures included adverse events, biomicroscopy, 
ophthalmoscopy, visual acuity, blood pressure, and pulse 
rate. Adverse events were coded according to the Medical 
  Dictionary for Regulatory Activities (MedDRA) classification 
scheme. An adverse event was determined by the investigator 
to be treatment-related if there was a reasonable possibil-
ity that it may have been caused by the study medication. 
Slit-lamp biomicroscopy was performed at 8 am at baseline 
and month 1 with findings reported on a scale of 0 = none, 
0.5 = trace, 1 = mild, 2 = moderate, and 3 = severe.
Patient-reported change in eye appearance (yes or no) 
and acceptability of treatment were evaluated using a written 
questionnaire at baseline and month 1. Physician-reported 
acceptability of treatment was also evaluated using a ques-
tionnaire at month 1.
The primary statistical analyses evaluated the modified 
intent-to-treat (mITT) population defined as all randomized 
patients who received at least one dose of study medication 
and had macroscopic hyperemia evaluated at all three time 
points at both the baseline and month 1 visits. As a   sensitivity 
analysis, the primary endpoint of macroscopic hyperemia 
was also evaluated in the per-protocol population of patients 
with no major protocol violations. Safety analyses evalu-
ated all randomized patients who received at least one dose 
of study medication and were seen at a postbaseline visit. 
Nominal data were analyzed using the Pearson chi-square 
test or Fisher exact test. Macroscopic hyperemia and IOP 
data were analyzed using analysis of variance models with 
treatment and site as main effects. The null hypothesis of 
noninferiority was that the mean peak change from baseline 
in macroscopic hyperemia for bimatoprost 0.01% was at 
least 0.5 grades greater than that for vehicle. Bimatoprost 
0.01% would be noninferior to the vehicle if the upper limit 
of the 95% confidence interval (CI) of the between-group 
difference (bimatoprost 0.01% minus vehicle) in the peak 
change from baseline hyperemia at month 1 was less than 
0.5. Within-group changes in IOP were analyzed using paired 
t tests. Changes in the percentage of patients with diurnal 
IOP (defined as the average of measurements taken at 8 am, 
12 pm, and 4 pm) of less than 18 mm Hg were analyzed using 
the McNemar test. Between-group differences in treatment 
acceptability were analyzed using the Wilcoxon rank sum 
test. The alpha level for statistical significance was 0.05.
A sample size of 192 patients (128 in the bimatoprost 
0.01% group and 64 in the vehicle group) was estimated to 
have 90% power to determine noninferiority of bimatoprost 
to vehicle in the primary endpoint, assuming a common stan-
dard deviation (SD) of 1.0 in the peak change from baseline 
macroscopic hyperemia. Based on an anticipated dropout rate 
of 10%, the planned enrollment was 216 patients.
Results
A total of 222 patients (151 in the bimatoprost 0.01% group 
and 71 in the vehicle group) at 15 sites were randomized to 
receive treatment. The study was completed by 95.4% of 
patients (144/151) randomized to bimatoprost 0.01% and 
93.0% of patients (66/71) randomized to vehicle. The most 
common reason for early discontinuation from the study was 
a protocol violation (2.6% of bimatoprost 0.01% patients and 
4.2% of vehicle patients).
The mITT study population included 98.2% (218/222) 
of all randomized patients. Baseline characteristics of these 
patients are listed in Table 1. Most patients were Caucasian 
and 78% were diagnosed with glaucoma in both eyes. The only 
statistically significant difference in baseline   characteristics 
between treatment groups was an   approximately 10-micron 
greater central corneal thickness in the bimatoprost 0.01% 
group (P = 0.017); this difference was not   considered to be 
clinically meaningful. The duration of latanoprost mono-
therapy run-in prior to the baseline visit ranged from at least Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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six weeks to more than two years for patients in this popula-
tion. Patients used latanoprost between 6 pm and 11 pm the 
night before the baseline visit.
There was no statistically significant difference between 
treatment groups in the mean peak macroscopic hyperemia 
severity score at the latanoprost-treated baseline. The mean (SD) 
peak score at the latanoprost-treated baseline was 0.32 (0.28) 
in the bimatoprost 0.01% group and 0.30 (0.29) in the vehicle 
group (P = 0.466). At month 1, the mean (SD) peak hyperemia 
score was 0.50 (0.51), or trace, in the bimatoprost 0.01% group 
and 0.32 (0.35) in the vehicle group (P = 0.004) (Figure 1).
After one month of bimatoprost or vehicle   treatment, 
the mean (SD) peak change in hyperemia from the latano-
prost-treated baseline was 0.18 (0.46) in the bimatoprost 
0.01% group and 0.02 (0.32) in the vehicle group. The 
between-group difference was 0.15 with a 95% CI of 
0.04, 0.26 (P = 0.009). As the upper limit of the 95% CI 
of the between-group   difference was within the predefined 
noninferiority margin of 0.5, bimatoprost 0.01% was non-
inferior to vehicle in the primary study endpoint of peak 
change from baseline macroscopic hyperemia. Results of the 
analysis of   macroscopic hyperemia in the per-protocol study 
  population, which excluded an additional 23   randomized 
patients due to protocol violations, were consistent with those 
in the mITT study population.
There were no statistically significant differences 
between treatment groups in the percentage of patients 
demonstrating a $1-unit increase in macroscopic hyperemia 
from baseline at any time point at month 1. The percent-
age of patients with a $1-unit increase in the severity of 
macroscopic hyperemia in the bimatoprost 0.01% and 
vehicle groups, respectively, was 8.2% and 1.4% at 8 am 
(P = 0.065), 4.1% and 1.4% at 12 pm (P = 0.432), and 4.1% 
and 0% at 4 pm (P = 0.181).
There were no statistically significant differences in mean 
IOP between the bimatoprost 0.01% group and the vehicle 
group at the latanoprost-treated baseline (Table 2). After one 
month of treatment with bimatoprost 0.01% or vehicle, IOP 
was reduced significantly in the bimatoprost 0.01% group 
(P # 0.002) and was increased significantly in the vehicle group 
(P , 0.001) at each time point. The mean change from   baseline 
IOP at month 1 ranged from -0.7 mm Hg to -1.3 mm Hg with 
bimatoprost 0.01% and from +3.3 mm Hg to +3.6 mm Hg with 
Table 1 Patient characteristics at baseline
Bimatoprost  
0.01% 
(n = 147)
Vehicle 
(n = 71)
Between-group   
P value
Mean age in  
years (SD)  
(range)
64.2 (11.5)
24–89
66.3 (10.7)
28–90
0.201
Sex, n (%) 0.694
Male 60 (40.8%) 27 (38.0%)
Female 87 (59.2%) 44 (62.0%)
Race, n (%) 0.115a
Caucasian 110 (74.8%) 47 (66.2%)
Black 33 (22.4%) 23 (32.4%)
Asian 4 (2.7%) 1 (1.4%)
Diagnosis 0.613
Ocular  
hypertension
30 (20.4%) 13 (18.3%)
(both eyes)
glaucoma  
(both eyes)
114 (77.6%) 55 (77.5%)
Ocular  
hypertension/
3 (2.0%) 3 (4.2%)
glaucomab
Mean central  
corneal thickness  
in microns (SD)c
555 (30) 545 (29) 0.017
Notes: aP value for black versus nonblack; bOne eye with ocular hypertension and 
the fellow eye with glaucoma; cAnalysis used the average value from both eyes of 
each patient.
Abbreviation: sD, standard deviation.
Severe (+3)
Moderate (+2)
Mild (+1)
Trace (+0.5)
None (0)
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Month 1
a
Bimatoprost 0.01% (n = 147)
Vehicle (n = 71)
M
e
a
n
 
p
e
a
k
 
s
e
v
e
r
i
t
y
 
o
f
 
h
y
p
e
r
e
m
i
a
Figure 1 Mean peak macroscopic hyperemia scores at baseline and month 1.
Notes: The between-group difference at month 1 was 0.17 (95% Ci: 0.06, 0.29). 
aP = 0.004 vs vehicle. error bars represent the standard deviation.
Table 2 Efficacy measure: intraocular pressure (mm Hg)
Bimatoprost 
0.01%  
(n = 147)
Vehicle 
(n = 71)
Between-group   
P value
Mean (SD) baseline IOP on latanoprost
8 am 18.2 (3.1) 18.0 (3.3) 0.292
12 pm 18.0 (3.2) 17.9 (3.4) 0.626
4 pm 17.6 (2.9) 17.2 (3.6) 0.250
Mean (SD) change from latanoprost-treated baseline  
IOP at month 1
8 am -1.0 (2.6)a +3.6 (3.9)a ,0.001
12 pm -1.3 (2.6)a +3.3 (4.0)a ,0.001
4 pm -0.7 (2.9)a +3.3 (3.5)a ,0.001
Note: aP # 0.002 for within-group change from baseline based on paired t test.
Abbreviations: sD, standard deviation; iOP, intraocular pressure.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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vehicle (Table 2). In the bimatoprost 0.01% group, the   percentage 
of patients with diurnal IOP , 18 mm Hg increased statistically 
significantly from 50.3% at the latanoprost-treated baseline 
to 66.0% at one month after replacement of latanoprost with 
bimatoprost 0.01% (P , 0.001), while in the vehicle group, the 
percentage of patients with diurnal IOP , 18 mm Hg decreased 
significantly from 56.3% at the latanoprost-treated baseline to 
21.1% at one month after replacement of latanoprost with vehicle 
(P , 0.001). Notably, among the 73 patients in the bimatoprost 
0.01% group who had diurnal IOP $ 18 mm Hg at the latano-
prost-treated baseline, 38.4% (28) had diurnal IOP , 18 mm Hg 
after replacement of latanoprost with bimatoprost 0.01%.
There were no statistically significant between-group 
differences in the proportion of patients with adverse events, 
treatment-related adverse events, or discontinuations due 
to adverse events. Adverse events were reported in 20.0% 
(30/150) of bimatoprost 0.01%-treated patients and 12.7% 
(9/71) of vehicle-treated patients. None of the adverse events 
were serious and only 2 of 150 patients in the bimatoprost 
0.01% group (1.3%) discontinued from the study due to 
adverse events (one patient due to photophobia and one 
patient due to conjunctival hyperemia, blurred vision, and eye 
  pruritus). The most common treatment-related adverse event in 
each treatment group was conjunctival hyperemia (Table 3).
On biomicroscopy, there were no statistically significant 
differences between treatment groups in the percentage of 
patients with a $1-unit increase from the baseline severity 
of any findings, including conjunctival hyperemia, in either 
eye (Table 4). In other safety evaluations, there were no 
significant differences between treatment groups in change 
from baseline visual acuity or ophthalmoscopic findings and 
there were no clinically meaningful differences between 
treatment groups in change from baseline blood pressure 
and pulse rate.
At month 1, treatment acceptability judged by both physi-
cians and patients was higher with bimatoprost 0.01% than 
with vehicle (P , 0.001). Physicians were very or extremely 
willing to continue 85.7% (126/147) of the patients in the 
bimatoprost 0.01% group on bimatoprost 0.01%, but were 
very or extremely willing to continue only 39.4% (28/71) 
of patients in the vehicle group on vehicle, most commonly 
because IOP was not low enough. Similarly, the percentage 
of patients who were very or extremely willing to continue 
on their study medication at the end of the study was higher 
in the bimatoprost 0.01% group (88.4%, 130/147) than in the 
vehicle group (52.9%, 37/70). The most common reason for 
patients being only somewhat willing or unwilling to continue 
on bimatoprost 0.01% was listed as “other” (neither “eye 
redness” nor “IOP not low enough”). Most patients in each 
treatment group (95.1%, 137/147 in the bimatoprost 0.01% 
group and 94.1%, 64/70 in the vehicle group) reported no 
change in the appearance of their eyes since the beginning 
of the study.
Discussion
A goal of therapy in glaucoma is to reduce IOP to a low 
target level while minimizing the side effects of treatment. 
A previous study demonstrated that efficacy is maintained, 
but the occurrence and severity of conjunctival hyperemia is 
reduced with bimatoprost 0.01% compared with   bimatoprost 
0.03%.18 The present study further demonstrated that in 
Table 4 Proportion of patients with a $1-unit increase in the 
severity of biomicroscopy findingsa
Finding Bimatoprost 
0.01%  
(n = 150)
Vehicle 
(n = 71)
Between-group   
P value
Any findingb 6.0% (9/150) 2.8% (2/71) 0.509
nuclear cataract 1.3% (2/150) 2.8% (2/71) 0.595
Conjunctival  
hyperemia
4.0% (6/150) 0.0% (0/71) 0.180
Superficial  
punctate  
keratopathy
0.7% (1/150) 0.0% (0/71) .0.999
eyelid margin  
crusting
0.7% (1/150) 0.0% (0/71) .0.999
Notes: aBiomicroscopy findings were graded on a scale of 0 = none, 0.5 = trace, 
1 = mild, 2 = moderate, and 3 = severe. All biomicroscopy findings with at least a 
1-unit increase in severity from baseline or screening to month 1 reported in any 
patient are listed; bOverall incidence of increased severity of biomicroscopic findings 
(ie, patients with increased severity of any finding).
Table 3 incidence of treatment-related adverse eventsa
Adverse event Bimatoprost  
0.01%  
(n = 150)
Vehicle 
(n = 71)
Between-group   
P value
Any adverse eventb 15.3% (23/150) 7.0% (5/71) 0.084
Conjunctival  
hyperemia
6.7% (10/150) 2.8% (2/71) 0.346
eye pruritus 2.7% (4/150) 1.4% (1/71) .0.999
Dry eye 2.0% (3/150) 1.4% (1/71) .0.999
Blurred vision 1.3% (2/150) 1.4% (1/71) .0.999
Foreign body  
sensation
0.7% (1/150) 1.4% (1/71) 0.540
headache 0.0% (0/150) 1.4% (1/71) 0.321
Keratoconjunctivitis  
sicca
0.0% (0/150) 1.4% (1/71) 0.321
scleral hyperemia 0.0% (0/150) 1.4% (1/71) 0.321
Notes: aAll treatment-related adverse events reported in $1% of patients in either 
treatment group in the safety population are listed; bOverall incidence of treatment-
related adverse events (ie, patients with one or more treatment-related adverse 
events).Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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patients controlled on latanoprost who replaced latanoprost 
monotherapy with bimatoprost 0.01% monotherapy, the 
conjunctival hyperemia attributed to bimatoprost 0.01% was 
no worse than that seen in patients who replaced latanoprost 
monotherapy with vehicle. Moreover, bimatoprost 0.01% 
statistically significantly reduced the mean IOP from the 
latanoprost-treated baseline. Bimatoprost 0.01% was as 
well-tolerated as the vehicle and was well-accepted by both 
patients and physicians.
Using a predetermined noninferiority margin of 0.5, 
bimatoprost 0.01% was noninferior to the vehicle in the mean 
peak change from baseline hyperemia scores at month 1. The 
difference between the bimatoprost 0.01% and vehicle groups 
in the change from baseline peak hyperemia scores at month 1 
was only 0.15, a difference that we do not consider to be clini-
cally meaningful. Further, there were no statistically signifi-
cant differences between the bimatoprost 0.01% group and 
the vehicle group in the proportion of patients who had at least 
a 1-grade increase in hyperemia from baseline to month 1 
at any time point. Adverse event reports of conjunctival 
hyperemia were consistent with a low, reduced occurrence of 
conjunctival hyperemia associated with bimatoprost 0.01% 
compared with the original bimatoprost 0.03% formulation. 
There was no statistically significant difference in adverse 
event reports of hyperemia between the bimatoprost 0.01% 
group (6.7%) and the vehicle group (2.8%). In contrast, 
large studies evaluating bimatoprost 0.03% have reported 
  conjunctival hyperemia as an unsolicited adverse event in 
21% to 46% of treated patients.20–22 Although the duration 
of those studies was longer (3 or 6 months), conjunctival 
hyperemia associated with prostaglandin analog therapy 
typically has an early onset; in the 1-year pivotal trials of 
bimatoprost 0.03%, the median time to onset of   conjunctival 
hyperemia was 14 days after the initiation of therapy.8 The 
low proportion of patients (4.9%) reporting a change in 
eye appearance in the present study is also consistent with 
an improved side effect profile and reduced conjunctival 
hyperemia with the bimatoprost 0.01% formulation. Only 
one patient (0.7%) discontinued from bimatoprost 0.01% 
treatment due to conjunctival hyperemia.
In the Advanced Glaucoma Intervention Study, visual 
field loss was minimized in patients who consistently 
achieved IOP less than 18 mm Hg.23 In the present study, 
a statistically significant mean decrease in IOP and increased 
likelihood of achievement of diurnal IOP less than 18 mm 
Hg was observed in patients who replaced latanoprost with 
bimatoprost 0.01%. These results are consistent with the 
literature.14,15,18,24 Patients who replaced latanoprost with 
vehicle experienced a   significant increase in IOP, but 
the magnitude of the increase was smaller than might be 
expected, given that latanoprost has typically been shown 
to reduce IOP by approximately 30%.1 These results could 
suggest a possible placebo effect or, perhaps more likely, a 
continued effect of latanoprost at the month 1 study visit, as a 
previous study has shown that one month may be inadequate 
for complete washout of the effect of previous latanoprost 
treatment.25
The bimatoprost 0.01% formulation and the vehicle 
used in the study are preserved with benzalkonium chloride 
(BAK), which appears to promote penetration of topically 
applied medications by disrupting intercellular adhesions in 
the corneal epithelium,26 thus allowing lower concentrations 
of drugs to be applied to the ocular surface. Although BAK 
and drug formulations containing BAK have been reported to 
cause cell or ocular surface damage in cell culture and rabbit 
model systems,27–33 the clinical significance of these findings 
is unknown. Clinical studies that have evaluated travoprost 
containing BAK compared with travoprost containing an 
alternative preservative have shown no improvement in 
clinical signs or other safety measures with the BAK-free 
  travoprost formulation.34,35 Similarly, no improvement in 
safety or tolerability has been observed with preservative-free 
tafluprost compared with tafluprost preserved with BAK.36 
The concentration of BAK in bimatoprost 0.01% is the same 
as that in latanoprost 0.005%, which has been successfully 
used for many years37,38 and because the prostaglandin 
  analogs are dosed only once-daily, preservative exposure and 
accumulation are minimized. In the phase 3 study   comparing 
bimatoprost 0.01% with the original bimatoprost 0.03% 
  formulation, bimatoprost 0.01%   demonstrated improved 
  tolerability over 12 months compared with bimatoprost 
0.03% and no patients discontinued from bimatoprost 
0.01% treatment due to adverse events that could be related 
to corneal toxicity, such as corneal erosions or punctate 
keratitis.18
There are several limitations to the present study. Because 
the study duration was one month with no interim follow-up 
visits, hyperemia that might occur after longer-term 
  treatment with bimatoprost 0.01% could not be evaluated 
and   hyperemia could have occurred and resolved prior to 
month 1 in some patients. Further, the study population was 
restricted to patients who were on latanoprost monotherapy 
and did not have significant hyperemia at screening. The fact 
that the mean IOP increased significantly by more than 
3 mm Hg in patients who switched to the vehicle   suggests 
that the study population was responsive to latanoprost. Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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  However, it is likely that patients who are switched directly 
from latanoprost to bimatoprost demonstrate less hyperemia 
than   treatment-naive patients.5,39 Further studies will be 
needed to evaluate conjunctival hyperemia associated with 
bimatoprost 0.01% use in treatment-naive patients.
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